Related by context. All words. (Click for frequent words.) 73 iv 70 vii 66 iii 65 viii 64 ix 63 ii 60 xviii 58 xvi 58 xxii 58 xiii 58 xix 57 xv 57 xi 57 xii 56 Pure Biofuels ability 55 xvii 55 xxvi 55 xiv 54 xxi 54 xxiv 53 collect reinsurance recoverables 53 Immtech clinical trials 53 Immtech scientists 53 iii iv 52 xxv 51 xxiii 50 DSL.net s 49 risksassociated 49 ourability 49 xxvii 49 #.#-# b [002] 48 ac ti 48 xxxii 47 xxviii 47 limitedto 47 changesin 47 Textainer expectation 47 rapid technological 47 [013] 47 materially adversely affect 46 HANA MAX 46 resulting therefrom 46 #.#-# b [001] 46 orother 46 Cerro Negro concession 46 without limitation 45 substantial indebtedness 45 Projects Initiation 45 P. #a 45 related thereto 45 ecommerce marketplaces 45 GrowthWorks refers 45 ti es 45 aux côtés 45 retrocessional coverage 45 minerals inc 45 Lenfest ii 45 CAUTION ANY ATTEMPT 44 contingent guaranties 44 general economicconditions 44 unanticipated difficulties 44 theCompany 44 j 44 orotherwise 44 Det är 44 f h 44 ability tosuccessfully 44 rhan 44 governmental approvals 43 vQsQn 43 connection therewith 43 vl 43 lender consents 43 SURETY LICENSES c 43 h 43 love veronica Mars 43 associated therewith 43 h g 43 theability 43 vii viii 43 valore 43 flwyddyn 43 ma il 43 El Boleo Project 43 i g 43 withrespect 43 notlimited 43 representations warranties covenants 43 paul dev da 43 ii iii 43 Jekk 43 examinations vaccinations spaying 43 § #-#-# b [003] 43 theavailability 42 y u 42 i 42 deben 42 prepayment speeds loan originations 42 ftit 42 h r 42 See USSG § #B#.# 42 Second Supplemental Indenture 42 including withoutlimitation 42 CompanyaEUR TM s 42 i #.# subds 42 ghax ma 42 inni 42 sul sito 42 en vertu de la 42 legal proceedings xxi 42 otherfactors 42 Services LLC SPIAS 42 h w 42 risks associated 42 gli di 42 r h 42 LOVE YOU ALL 42 rā 42 difrifol 42 gwaith 42 li il 42 biex 42 relating 42 involverisks 42 del sistema 42 permitting timelines 42 w # yQ 42 hong kong > 42 c html plugins 42 tkun 42 adversely affect 42 li kien 42 proba 42 ddau 42 refinance indebtedness 42 u h 42 DTR #.#.# b 42 mwy 42 Offerors Commercial applies 41 deploy MDCE services 41 Iusacell Celular 41 krn 41 u ma 41 #.# subd [003] 41 • vaibhav sir 41 u t 41 mettre un 41 ` rk 41 risks associated therewith 41 y r 41 No reira 41 mhw ` 41 risks associatedwith 41 = strlen 41 statementsregarding 41 iehor 41 rhoi 41 éxito 41 holl 41 bland annat 41 incur unanticipated 41 successfully integrate 41 ta li 41 fac 41 USC § #f 41 g h 41 competitively procured pursuant 41 p r 41 rhai 41 risksand uncertainties 41 SumTotal Systems filings 41 n h 41 f [001] 41 - Effect [009] 41 inventory obsolescence 41 § #.#-# [007] 41 Di seguito 41 kulhadd 41 Kung sila pa rin 41 results ofoperations 41 l o 41 TCA § #-#-# [003] 41 VIOXX Lawsuits 41 r t 41 iyung 41 - -Abotsi 41 sono stati 41 successfully commercialize 41 Partially offsetting 41 Pa.RAP 41 wiehed 41 ar hyn o bryd 41 ke na 41 ÿÿ ÿþÿÀ ÿ ® 41 dpa rt 41 garantie 41 b 41 Crisa acquisition 41 CFR § #.# [006] 41 dan il 41 relatedto 41 un problema 41 jista 41 mw http :/ finance.yahoo.com 41 affirmative covenants 41 ka wa 41 § #-#-# b [001] 41 xoghol 41 #.#-# Equal Opportunity 41 även 41 filingswith 40 PharMerica LTC Transaction 40 Colo. Sess 40 om att 40 neque 40 asupra 40 postretirement benefit obligations 40 ac mae'n 40 di che 40 ko te 40 InnSuites Hotels 40 Heska reliance 40 consiste 40 enti 40 noti 40 affecting mortality morbidity 40 sobre todo 40 dpa fp 40 datos 40 dawk 40 nancial 40 huwa 40 dejjem 40 aux actionnaires 40 tulad ni FG 40 denna 40 de ses 40 SonoPrep device 40 estos 40 di cui 40 assorted pigments resins 40 BY AN ENTRANT 40 DELETE OR EDIT COMMENTS 40 prices drydocking 40 See USSG § #A#.# 40 r n 40 regarding Heska 40 o ngā 40 ma li 40 i ngā 40 ang nandiyan malabo na 40 ARLP Partnership 40 tân 40 taghhom 40 xxix 40 h u 40 LPM TM 40 tenant bankruptcies 40 swyddogion 40 Merger Transactions 40 xxxv 40 otherrisks 40 xxxiii 40 USC § #a [002] 40 Ferlay J et al 40 de forma 40 thereunder 40 NASD Marketplace Rule 40 CFR #.# [002] 40 r l 40 i# implanters 40 § #.#-# [004] 40 yn gallu 40 risks anduncertainties 40 hemm 40 multiple lease terminations 40 coûts 40 adversely affecting Cubist 40 aresubject 40 CFR § #.# [005] 40 t r 40 la de las 40 wā 40 thereof 40 relat ed 40 subparagraph B 40 ni wedi 40 yn iawn 40 Mago ® 40 i roto 40 h y 40 las condiciones 40 Partially offset 40 y h 40 OSI Pharmaceuticals filings 40 kienet 40 Legal #.# 40 n h r 40 tonu 40 #.#-# [020] 40 d Reflects 40 cael 40 requirements xxii 40 primarily attributable 40 Johnell O 39 løp 39 postretirement benefits 39 affecting IsoTis 39 theSecurities 39 technological obsolescence 39 uncertaintiesthat 39 i sicrhau 39 #.# subd [004] 39 DR #.#.# 39 bone marrow fibrosis 39 communicate differentiations effectively 39 cyhoedd 39 ymateb 39 concerning InfoSonics 39 ` vQsQn 39 Partially offsetting these 39 perder 39 CFR § #.# [004] 39 quello 39 impactof 39 DIP Loan 39 i te 39 ghandu 39 className nodes nodes.length = 39 manufacture PolyHeme 39 defnyddio 39 f o 39 ffordd 39 yno 39 materially adversely affected 39 USC § #u 39 informa 39 ahjar 39 d Represents 39 o 39 PLAVIX R patent 39 ikun 39 -Civilian Nuclear 39 xiv unanticipated 39 dpa hl 39 iaculis 39 CFR § #.# [008] 39 g o 39 Bo Scaife TE 39 w l 39 [047] 39 heddlu 39 #.#-# Instructions 39 dpa wh 39 gvern 39 relación 39 acquisitions dispositions 39 propia 39 EXPENSES Employee Compensation 39 Thalomid R 39 # wQ 39 yn gweithio 39 Liability Lawsuits 39 il gvern 39 @ gn 39 energía 39 jo bo 39 Direct xi Indirect 39 aún 39 REIT xi 39 HealthGate ability 39 u li 39 vi vii 39 humana 39 les en 39 passenger Silver Whisper 39 yr ysgol 39 economicconditions 39 kollu 39 gwasanaeth 39 tarjeta de 39 wv ` 39 ngä 39 Income Tax Regs 39 areforward looking 39 haga 39 OCGA § #-#-#.# 39 tant 39 CFR § #.# [007] 39 fis 39 CFR #.#b 39 ar ei 39 l u 39 qW 39 dpa amc 39 causeactual results 39 principally attributable 39 VIOXX Product 39 gallu 39 hwn 39 rhaid 39 dpa nr 39 vii IBC 39 o tēnei 39 counterparty creditworthiness 39 gwybodaeth 39 NET INCREASE IN 39 en tant 39 dpa si 39 fringilla 39 LOPROX R 39 i fod 39 il li 39 h o 39 ddim 39 biss 39 party payors 39 yn un 39 Company noncontributory defined 39 två 39 CFR § #.# [003] 39 Equinix filings 39 heading RISK FACTORS 39 alguna 39 Risks uncertainties 39 § #a [002] 39 falta de 39 o h 39 xi hadd 39 sydd 39 llawn 39 bhí 39 regardingthe 39 que usted 39 haber 39 l istess 39 postretirement 39 t h r 39 Shire plc Attention Deficit 39 pricing pressures 39 Prelude SkinPrep Systems 39 securityholder approvals 39 #.# subd [006] 39 d h 38 affecting Amarin 38 diminishing quantities 38 theforward looking 38 nies li 38 jkun 38 e nei 38 nuove 38 i te tau 38 arcu 38 en caso de 38 retail industries repositionings 38 representa 38 Consists 38 adversely impact 38 -DEAD BODY 38 See USSG § #D#.# 38 estado 38 VIACOM INC. AND SUBSIDIARIES 38 Cafodd ei 38 - Effect [005] 38 Mae'n 38 l h 38 eu ar 38 #.# subdivision [004] 38 się 38 Gvern 38 Oligator R oligonucleotides iv 38 la forma 38 gathering compressing treating 38 hi'n 38 forward lookingstatements 38 cmt 38 zmien 38 kōrero 38 regulatory authorizations 38 OCGA § #-#-# [005] 38 f g 38 Repl. 38 uts 38 heading ITEM 1A 38 #Me 38 principali 38 że 38 incurrence 38 historicalfacts 38 xi haga 38 Chan eil 38 pharmacotherapeutics 38 frm delhi plz 38 l li 38 Company periodic filings 38 wQ @ b 38 Gastroesophageal Reflux 38 cyhoeddus 38 work stoppages slowdowns 38 Mae'r heddlu 38 See USSG 38 Companys 38 CFR #.# [006] 38 APTIMA HPV assay 38 Freedom2 Holdings Inc. 38 ka fa 38 thereby negatively impacting 38 Refinancing Transactions 38 Unearned Premiums 38 § #.# subd [005] 38 #.# 5T 38 chwilio am 38 hafna 38 ddim wedi 38 Dalvik VM 38 USED IN FINANCING ACTIVITIES 38 Inside INdiana Host 38 diwethaf 38 digwyddiad 38 SciClone filings 38 yn mynd 38 ymlaen 38 de titres 38 es 38 Nō reira 38 cierto 38 looking statements.These 38 o l 38 HF Lenfest member 38 o t 38 mensaje 38 consiste en 38 â'r 38 documento 38 nisl 38 los dos 38 og av 38 Sensipar ® 38 gweithio 38 yn parhau 38 te ki 38 de nosotros 38 NYCRR #.# [001] 38 ghax il 38 USC § #c 38 dyfodol 38 ating 38 constante 38 Yomiuri Shimbun Distributed 38 ý Q 38 paul gordon 38 obtaining regulatory approvals 38 nuong 38 li qed 38 ghax 38 § #-#-# [005] 38 requisite stockholder 38 eg 38 ALS Analytical 38 sit amet 38 NET DECREASE IN 38 de l' activité 38 respect thereto 38 resultof 38 forwarda ^ looking 38 suchforward looking 38 ha dado 38 DECREASE IN CASH AND 38 vii Dynamic 38 gyfer 38 portant 38 mostra 38 que nos 38 av og 38 f r 38 og til 38 permette di 38 darba 38 symud 38 l l 38 RC #.# B [001] 38 mai te 38 unanticipated 38 ultimate recoverability 38 se han 38 globale 38 programas 38 problema 38 adversely affect FNB 38 Shire Attention Deficit 38 PolyHeme successfully 38 y wedi 38 l y 38 y digwyddiad 38 ang dahilan 38 dpa ry 38 du marché 38 heb 38 TranSwitch indebtedness 38 hekk 38 InSite Vision filings 38 wara li 38 ah HONE en siss 38 IRC § 38 empleados 38 thereto 38 § #-#-# [004] 38 riesgo 38 tieghu 38 § #-#-#.# 38 expan 38 WpHG mit dem Ziel 38 di aver 38 Partnered Brands segment 38 lugares 38 em Ponta Delgada 38 reserve estimations 38 market fluctuations investee 38 - Effect [003] 38 j'aime 38 dak li 38 wybodaeth 38 bhal 38 pY @ q 38 reduced workforces scarcity 38 e h r 38 OCGA § #-#-# [007] 38 ana te 37 National de Statistica 37 eu bod yn 37 el desarrollo 37 iii Cubist 37 fydd yn 37 - -seemingly unquenchable 37 SCHIP Extension 37 constitutes discloseable transaction 37 ¿ Cómo 37 pajjiz 37 Fed.R.Civ.P. 37 sylw 37 Registrant 37 r y 37 distribu 37 #.#-# Offeror Representations 37 -Tommy Salo 37 fueron en 37 ullamcorper 37 är det 37 awr 37 todas 37 Unitholder liability 37 transactions contemplated 37 GASFRAC 37 eller 37 activités 37 thusa 37 fod yn 37 Scheduler Plus 37 Black Canyon mica 37 kienu 37 without limitation Terremark 37 deCODE filings 37 fejn 37 parhau i 37 theseforward looking 37 gweld 37 installata sul proprio pc 37 signifi 37 Roedd yn 37 postretirement benefit plans 37 jekk 37 Stapling Proposal 37 qatt 37 yr yn 37 - Effect [016] 37 aktar 37 h l 37 sut y 37 natin kung 37 liabilities slippage 37 lo que se 37 fluctuations 37 ¨ ¤ 37 falta 37 - -Commey 37 caus 37 #,# -SPIN BOLDAK Afghanistan 37 qatt ma 37 Exelbine 37 menores 37 periodic redeterminations 37 arebased 37 próximos 37 Questcor intellectual property 37 te o te 37 aproximadamente 37 operativo 37 Bluebeam Conversion Server 37 d' une nouvelle 37 SIMOX SOI 37 Subject 37 qed 37 collectibility 37 Certifications Commercial Items 37 SEC Rule #g# 37 party VLSI fabrication 37 Hyperactivity Disorder ADHD 37 se debe 37 det er 37 #.#-# [016] 37 hynny'n 37 fue 37 otras 37 again replying msg 37 spelet 37 Bioaccelerate compounds under 37 adverse determinations 37 ofsuch 37 Important factors 37 stata 37 mo ba 37 capture exosomes 37 las y 37 utilize FFO NOI 37 - Effect [002] 37 Factors influencing 37 Form 8K #K 37 ects 37 ddamwain 37 Secure Computing periodic 37 Fourth Supplemental Indenture 37 gwasanaethau 37 equity accounted investees 37 b Reflects 37 generación 37 str = i 37 Julius Peppers DE 37 TP# CETi 1 37 postretirement benefit 37 blir 37 har 37 mayroong 37 resultados 37 equ 37 OTHER INCOME EXPENSES 37 un acuerdo 37 qabel 37 FierceGovernmentIT tracks 37 digwydd 37 inaccuracy therein 37 · Î 37 eto 37 Maimon Mine 37 nei ki 37 hefyd yn 37 purchaserâ € ™ 37 -PROCTOR Water 37 product discontinuances 37 xv licensing 37 fuq 37 unfavorable geologic 37 är och 37 ba ne ba 37 Flash Player uguale o 37 renegotiation nullification 37 TrueKnowledge Platform TM 37 #.#-# Affirmative Action 37 Confidential Offering Memorandum 37 kan du 37 jaghmel 37 HEI Quarterly Report 37 CORLUX CORT # 37 forwardlooking statements 37 bod yn 37 * ls 37 visit http:/www.nationwide.com 37 punto de 37 OneBeacon filings 37 TriPath Oncology 37 novel ZFP TFs 37 ies 37 thepotential 37 efectos 37 le agus 37 SeraCare competitors 37 Cafodd y 37 yr wyf 37 persistency mortality 37 SOLTAMOX 37 xvi beer 37 che è 37 ohra 37 § #-#-# [002] 37 eu yn 37 wrth 37 li ma 37 nhw 37 - Effect [007] 37 Absentee Telephone 37 cect u# china 37 tipo 37 work stoppages quarantines 37 en cuenta 37 w illus 37 Waratah Coal filings 37 contingently liable 37 applicable 37 - Operating [006] 37 PGP Acquisition 37 market PolyHeme commercially 37 CFR #.# [008] 37 referenced herein 37 unrhyw 37 pagar 37 SANCTURA SANCTURA XR VANTAS 37 Protonix ® 37 excepto 37 Private Securities LitigationReform Act 37 gyud na 37 Mitsue Pipelines 37 mwy o 37 OraTest R 37 comunicado 37 supplémentaires 37 gafodd eu 37 ac mae'r 37 d SIGA 37 anyforward looking 37 isipin 37 - Operating [020] 37 wala ka 37 #,#,# #,#,# -shameful betrayal 37 Slightly offsetting 37 LOUIS Oshiomogho Atogwe 37 xviii currency 37 cyngor 37 o fewn 37 § #-#-# [006] 37 uy 37 #.#-# [005] 37 qué 37 - Non GAAP [009] 37 kumar singh mam im 37 associatedwith 37 y tu allan 37 kieku 37 ` @ gn 37 jigi 37 inversión 36 elecciones 36 parte 36 marketconditions 36 lejos 36 como para 36 ond yn 36 wynebu 36 hon yn 36 ano ba 36 offuture 36 L imited 36 Varvarinskoye Project 36 hacen 36 Unfavorable 36 - Effect [006] 36 Proposed Arrangement 36 commercialize ZYFLO CR 36 prévue 36 successfully commercialize Silenor 36 una versione del 36 neto 36 ta l 36 de la société 36 Regulation XXX 36 importante 36 cyfnod 36 - -Billeaudeau 36 y cynulliad 36 Charlie Manuel flips 36 capitated contracts 36 kien 36 anodd 36 non si ha 36 suchstatements 36 ng pag 36 ¤ ¤ ¤ ¤ 36 CFR #.# [005] 36 distinguishing GigaBeam products 36 wrth i 36 Wikifamilies 36 au cours des 36 RISKS AND UNCERTAINTIES 36 fått 36 NJAC #:#-#.# 36 e# periodic 36 irls 36 poplu 36 novità 36 differ materially 36 themanagement 36 EXPENSES Interest 36 Liquor Stores LP 36 tels que 36 - Adjusted [003] 36 EMPOWER pivotal trial 36 modèle 36 ayuda 36 Statements Statements 36 kif 36 uu 36 quant à 36 dimesylate Attention Deficit 36 Offerors Commercial Items 36 noen 36 si se 36 o nga 36 mewn 36 área 36 eTelcharge.com Inc. 36 gan fod 36 eraill 36 @ y qW 36 adeilad 36 stockholder approvals 36 uncertainties 36 i'w 36 § #c 36 en sus 36 dette 36 fuq il 36 ffect 36 * ked 36 Gymraeg 36 araw na 36 subsections b 36 ac fe 36 saranno 36 § #.# [004] 36 IVAX Diagnostics 36 necessarily reflect Dawn.com 36 AspenTech periodic reports 36 ifanc 36 haere 36 arwain 36 facsimile transmission 36 Cautionary Disclosures 36 8 mone thake 36 Excludes goodwill 36 t h eir 36 -Amos Harel Haaretz Correspondent 36 alemtuzumab MS 36 § #E 36 laquelle 36 competing steel minimills 36 FAR #.#-# Instructions 36 withoutlimitation 36 couldcause 36 transportation storage terminalling 36 estructura 36 BioSante licensees 36 ° í 36 donald sues me 36 expenses associated therewith 36 Financing Condition 36 CFR § #.# [002] 36 b Vernon Supp 36 indemnification obligations 36 Ë 36 rapid technological advances 36 - - Net [031] 36 tēnā 36 substantiate CytoCore expectations 36 - - Net [023] 36 Http :/ www.irinnews.org copyright 36 EPIXTAR 'S 36 Analyte Specific Reagent 36 isa't isa 36 prepayment speeds loan 36 Analysis C.1 Strengths 36 qu'en 36 la situación 36 ar eu 36 debería 36 ardal 36 asset impairments 36 #.#A [005] 36 SEK -#.# -#.# [003] 36 STATEMENTS Certain 36 Consists primarily 36 Company 36 www.yomiuri.co.jp index e.htm Copyright 36 galw 36 render PolyHeme obsolete 36 nifer o 36 AXXX 36 presentar 36 @ vn 36 dependent upon 36 yna 36 Bioenvision dependence